recommended for patients who have previously experienced >1 flare but have infrequent flares (<2/year). For patients with less frequent flares and no tophi, the potential clinical benefit of ULT would be lower than the ULT benefit for patients with more burdensome gout. In a single study (moderate certainty of evidence), patients with â‰¤2 previous flares (and no more than 1 gout flare in the preceding year) randomized to receive febuxostat (versus placebo) were less likely to experience a